Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

201.09 +2.46 (+1.24%)
Streaming Delayed Price Updated: 1:40 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
83 84 Next >
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they're in your portfolio. 
Via Benzinga
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. 
Via Benzinga
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
The drugmaker has convincingly laid to rest the biggest threat to its top line. 
Via The Motley Fool
Abbvie Stock Price Analysis – A Post-Humira Dip, New Drug Hopes, And Election Buzz – Is Now The Time To Buy?
With the loss of Humira’s exclusivity and a recent dip in stock value, many are questioning the future trajectory of AbbVie stock. 
Via Talk Markets
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
A look at the moves made by Viking Fund management in the third quarter, including the exits and new stakes and fund's largest positions at the end of Q3. 
Via Benzinga
2 Dividend Stocks to Buy Hand Over Fist in November
These companies have solid businesses and excellent dividend growth track records. 
Via The Motley Fool
Smart Money Is Betting Big In ABBV Options
 
Via Benzinga
Seeking Beta
While the “Trump rally” appears to have just begun, one of its initial hallmarks is that investors want beta. 
Via Talk Markets
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy. 
Via Benzinga
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, predicting significant stock outperformance. 
Via Benzinga
Navigating 14 Analyst Ratings For AbbVie
 
Via Benzinga
AbbVie Stock Drops 12% On Schizophrenia Drug Setback: Should You Buy The Dip?
AbbVie reports disappointing mid-stage data for its schizophrenia drug. 
Via Talk Markets
This Is What Whales Are Betting On AbbVie
 
Via Benzinga
My Favorite Dividend King to Buy in November
This Dividend King truly wears the crown. 
Via The Motley Fool
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why AbbVie Stock Was Getting Mashed on Monday
A splashy recent acquisition by the company might not be panning out. 
Via The Motley Fool
What's Going On With Bristol-Myers Squibb Shares Monday?
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:ABBV) announced that its Phase 2 EMPOWER trials did not meet... 
Via Benzinga
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company's broader drug pipeline. 
Via Benzinga
What the Options Market Tells Us About AbbVie
 
Via Benzinga
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
 
Via Benzinga
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for next steps. 
Via Benzinga
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
AbbVie stock also tumbled after its experimental schizophrenia treatment failed in two Phase 2 studies. 
Via Investor's Business Daily
3 Spectacular High-Yield Dividend Stocks to Buy in November
High yields aren't a warning indicator with these three stocks. 
Via The Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
2 Dividend Kings That Would Have Doubled Your Money in 5 Years
You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends. 
Via The Motley Fool
Dividend Watch: Three Companies Boosting Quarterly Payouts
Everybody loves dividends, as they provide a passive income stream. Recently, three companies have announced payout increases. Let’s take a closer look at each. 
Via Talk Markets
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025
Eli Lilly's price pullback is an opportunity worth 25%, with analysts' sentiment firming around the $1000 level. New highs are likely by early 2025. 
Via MarketBeat
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors. 
Via MarketBeat
Topics Intellectual Property
High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight
High-yielding AbbVie is on track for another 20% gain, which could happen by the end of the year. Analysts are raising their targets, leading to higher prices. 
Via MarketBeat
Topics Intellectual Property
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
83 84 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.